Regulus Therapeutics
RGLS
#7074
Rank
C$0.77 B
Marketcap
C$11.15
Share price
0.00%
Change (1 day)
428.99%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -C$66.2 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -C$63.15 Million a decrease over its 2023 earnings that were of -C$40.23 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -C$66.2 Million4.84%
2024 -C$63.15 Million56.97%
2023 -C$40.23 Million6.51%
2022 -C$37.78 Million2.53%
2021 -C$36.84 Million93.59%
2020 -C$19.03 Million-15.41%
2019 -C$22.5 Million-64.46%
2018 -C$63.29 Million-33.26%
2017 -C$94.83 Million-13.98%
2016 -C$0.12 Billion44.77%
2015 -C$76.16 Million-1.63%
2014 -C$77.42 Million203.6%
2013 -C$25.5 Million8.65%
2012 -C$23.47 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
C$10.52 B-16,333.32%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
C$2.12 B-3,381.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
C$12.74 B-19,767.29%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
C$19.28 B-29,845.51%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
C$13.52 B-20,964.39%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-C$0.15 Billion 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-C$0.17 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
C$0.78 B-1,313.98%๐Ÿ‡บ๐Ÿ‡ธ USA